Amneal Pharmaceuticals (AMRX) Minority Interest (2018 - 2026)

Amneal Pharmaceuticals' Minority Interest history runs 9 years deep, the most recent figure standing at -$558000.0 for Q1 2026.

• On a quarterly basis, Minority Interest fell 100.77% year-over-year to -$558000.0 in Q1 2026; TTM through Mar 2026 was -$558000.0, a 100.77% decrease from a year earlier, with the FY2025 full-year figure at -$535000.0, down 100.82% from the prior year.
• Minority Interest eased to -$558000.0 in Q1 2026 per AMRX's latest filing, from -$535000.0 in the prior quarter.
• Across five years, Minority Interest topped out at $72.6 million in Q1 2025 and bottomed at -$558000.0 in Q1 2026.
• The 5-year median for Minority Interest is $37.1 million (2023), against an average of $38.2 million.
• Across the five-year window, Minority Interest soared 79.51% in 2023 and tumbled 100.82% in 2025, its largest moves.
• Year by year, Minority Interest stood at $24.9 million in 2022, then soared by 65.51% to $41.3 million in 2023, then surged by 57.35% to $65.0 million in 2024, then plunged by 100.82% to -$535000.0 in 2025, then retreated by 4.3% to -$558000.0 in 2026.
• Per Business Quant, the three latest AMRX Minority Interest figures stand at -$558000.0 (Q1 2026), -$535000.0 (Q4 2025), and $67.8 million (Q3 2025).